Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Lentigen has signed an exclusive licensing agreement with Cambridge Enterprise, the organization responsible for licensing technologies from the University of Cambridge, for a fundamental patent in the area of lentiviral vector technology.
Subscribe to our email newsletter
The technology was developed in the laboratory of Andrew Lever at the University of Cambridge. Following the acquisition of the Cell Genesys’s lentiviral patent portfolio in 2007 by GBP Capital, the majority shareholder in Lentigen, this license is said to further consolidate Lentigen’s intellectual property position.
Boro Dropulic, founder, president and chief scientific officer of Lentigen, said: “The patent broadly claims fundamental compositions of HIV-based lentiviral vectors that are currently widely used in research and clinical studies.”